Additionally, there were no statistically significant differences in the prevalence of comorbidities (such as hypertension, coronary heart disease, and stroke) and medication combinations (including metformin, α-glucosidase inhibitors, insulin secretagogues, insulin, RAAS inhibitors, calcium channel blockers, and statins) between the two groups. This evidence concerns the gene INS and hypertensive disorder.